SLC17A5

Across TCGA pan-cancer cohorts, SLC17A5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC17A5 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SLC17A5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC17A5 expression acts as an unfavorable survival marker.

BLCA, PRAD, and UCEC are the cancer types where SLC17A5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.131	0.471	.008	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ESCA	DFS	Median	All	0.146	0.533	.046	3	view →
COAD	OS	Median	All	0.235	0.678	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC17A5–BLCA (DFS)

Open the BLCA breakdown →